Officials with ViiV Healthcare said that their Phase3b/4 STRIIVING study, which evaluated the safety, efficacy, and tolerability of switching from an antiretroviral therapy (ART) to once-daily abacavir/dolutegravir/lamivudine (Triumeq) has met its primary endpoint. 

STRIIVING was a randomized, open-label, multicenter study that enrolled patients switching from a range of ART that included protease inhibitor (n=234), integrase strand transfer inhibitor (n=146), and non-nucleoside reverse transcriptase inhibitor (n=171)-based regimens. 

According to a release from GlaxoSmithKline and data presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, the study met its primary endpoint in showing that viral suppression was non-inferior for patients switching to Triumeq (HIV RNA <50 copies/mL in intention to treat efficacy; n=551): 85% (Triumeq) vs. 88% (existing ART); and per protocol (n=435): 93% vs. 93%.


Continue Reading

Patients who switched to the once-daily regimen reported higher treatment satisfaction score improvements as measured by the HIV Treatment Satisfaction Questionnaire (adjusted difference 2.4; 95% CI: 1.3, 3.5; P<0.001), according to the release.

Reference

1. Trottier B, Lake J, Logue K et al. Switching to Abacavir/Dolutegravir/Lamivudine combination (ABC/DTG/3TC FDC) from a PI, INI or NNRTI based regimen maintains HIV suppression.  Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21, 2015, San Diego, California

This article originally appeared on MPR